Sign in
Taking peopleNo phase

Multimodal Biomarkers Predicting Medication-Induced Adverse Effects in Children With ADHD

Key facts

Who runs it
National Taiwan University Hospital
Where
Taiwan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
90 people, planned
Started
1 Aug 2026
Expected to end
31 Jul 2029
Type of study
Observational
Treatments tested
  • methylphenidate
Record updated
28 October 2026

Who can take part

Age
6 years to 16 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Participants, between the ages of 6 and 16 must meet the DSM-5 criteria for ADHD
  • At the time of initial evaluation, participants must exhibit a score greater than 3 on the Clinical Global Impressions scale for ADHD Severity (CGI-ADHD-S)
  • Cognitive assessment of participants must demonstrate a Full-Scale Intelligence Quotient (FSIQ) greater than 80

Who cannot take part

  • Individuals with any prior exposure to pharmacological treatments specifically intended for managing ADHD symptoms will be excluded
  • Individuals with comorbid major psychiatric disorders-including autism spectrum disorder (ASD), psychotic disorders, mood disorders, or substance use disorders-will be excluded
  • Individuals with major neurological conditions, such as epilepsy or other central nervous system disorders, will be excluded
  • Individuals with serious systemic medical conditions, including diabetes mellitus or cardiovascular disease, will be excluded

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 6 and 16 years old?

This trial is currently available in Taiwan.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To build a multimodal model combining neuropsychological, neurophysiological, and metabolomic measures to identify biomarkers predicting MPH-induced adverse effects and their underlying mechanisms, supporting individualized risk assessment in clinical practice.

The group in the trial

  • ADHD GROUP

    Subjects with clinical diagnosis of ADHD according to the DSM-V criteria

    Treatment: methylphenidate

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multimodal Neurobiological Investigation of Biomarkers Predicting Medication-Induced Adverse Effects in Children With Attention-Deficit/Hyperactivity Disorder
Criteria questions
Built from NCT07900451, who can take part
Record updated
28 October 2026